Study of new drug for relapsed or hard-to-treat multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new medicine (GR1803) against a standard combination treatment for people whose multiple myeloma has come back or stopped responding to prior therapies. It aims to see if the new drug works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma that came back or did not respond to 1 to 3 prior treatments, including a proteasome inhibitor and lenalidomide.
- If you had only one prior treatment, you must have had no response or progression on lenalidomide.
- You have measurable signs of the disease in blood or urine tests.
- You are in generally good health with a performance status score of 0, 1, or 2 (able to care for yourself or up and about more than half the day).
- You have not received a therapy targeting BCMA (a protein on myeloma cells) before.
- You have not had allergic reactions to similar drugs and are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug for people with multiple myeloma, a type of blood cancer. It aims to see how safe and effective the treatment is for patients who are newly diagnosed or have relapsed after prior therapy.
This trial tests a new drug called GR1803 combined with another drug (an anti-CD38 antibody) for people with multiple myeloma who have already tried standard treatments. The goal is to see if this combination can help when other treatments have stopped working.
This Phase 2 study tests a combination of medicines (isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone) for multiple myeloma that has come back or did not respond to prior treatment. It may help by better controlling the myeloma after standard therapies have failed.
This trial tests a new drug combined with other medicines for people with multiple myeloma, a related condition called AL amyloidosis, or high-risk smoldering multiple myeloma. It aims to see if the combination is safe and effective.
This trial tests two different drug combinations for people newly diagnosed with multiple myeloma who are not getting a stem cell transplant right away. It compares one drug (elranatamab) to another (daratumumab), both given with a standard three-drug regimen called RVd Lite, to see which works better.
This trial tests a new experimental drug called CM336 for people with multiple myeloma that has come back or stopped responding to standard treatments. The drug may work by helping your immune system attack and destroy myeloma cells. If you join, you will receive the study treatment and be closely monitored to see how well it works and how safe it is.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.